# Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin

> **NCT04482569** · PHASE1 · COMPLETED · sponsor: **Evopoint Biosciences Inc.** · enrollment: 88 (actual)

## Conditions studied

- Bacterial Infections

## Interventions

- **DRUG:** XNW4107

## Key facts

- **NCT ID:** NCT04482569
- **Lead sponsor:** Evopoint Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-10
- **Primary completion:** 2021-02-28
- **Final completion:** 2021-09-30
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2023-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04482569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04482569, "Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04482569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*